| Company/Division name | Garonit Pharmaceutical, Inc. |
| Parent company | Garonit Pharmaceutical, Inc. |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 100 |
| Year reshoring announced: | 2025 |
| Year reshoring implemented or to be implemented: | 2027 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 46.1 |
| Country(ies) from which reshored: | India |
| City reshored to: | New Windsor |
| State(s) reshored to: | NJ |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | chlorhexidine gluconate; antiseptics |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Government Incentives, Impact on domestic economy, Skilled workforce availability/training |
| Government Incentive dollar amount: | 7,600,000 |
